Abbott MediaRoom (Product) http://abbott.mediaroom.com/ Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care http://abbott.mediaroom.com/2017-03-19-Late-Breaking-Data-Shows-the-CardioMEMS-HF-System-is-Effective-in-Reducing-Heart-Failure-Hospitalizations-and-Cost-of-Care - Presented at ACC and published in Journal of American College of Cardiology, the CardioMEMS™ HF System offers sustained benefits for patients suffering from symptomatic heart failure Sun, 19 Mar 2017 14:00:00 -0400 http://abbott.mediaroom.com/2017-03-19-Late-Breaking-Data-Shows-the-CardioMEMS-HF-System-is-Effective-in-Reducing-Heart-Failure-Hospitalizations-and-Cost-of-Care Late-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease http://abbott.mediaroom.com/2017-03-18-Late-Breaking-Data-on-Abbotts-MitraClip-R-System-Show-Continued-Benefit-for-People-with-Mitral-Regurgitation-Most-Common-Heart-Valve-Disease - 92.8% procedural success observed in reducing leaky heart valve Sat, 18 Mar 2017 12:30:00 -0400 http://abbott.mediaroom.com/2017-03-18-Late-Breaking-Data-on-Abbotts-MitraClip-R-System-Show-Continued-Benefit-for-People-with-Mitral-Regurgitation-Most-Common-Heart-Valve-Disease Data on Absorb Bioresorbable Stent Show Comparable Outcomes to Leading Drug-Eluting Stent Between One and Two Years http://abbott.mediaroom.com/2017-03-18-Data-on-Absorb-Bioresorbable-Stent-Show-Comparable-Outcomes-to-Leading-Drug-Eluting-Stent-Between-One-and-Two-Years - Results emphasize importance of proper vessel sizing and following current instructions for use for optimal clinical outcomes Sat, 18 Mar 2017 10:45:00 -0400 http://abbott.mediaroom.com/2017-03-18-Data-on-Absorb-Bioresorbable-Stent-Show-Comparable-Outcomes-to-Leading-Drug-Eluting-Stent-Between-One-and-Two-Years New Study Results May Lead to a New Standard of Care for In Vitro Fertilization Treatment http://abbott.mediaroom.com/2017-03-08-New-Study-Results-May-Lead-to-a-New-Standard-of-Care-for-In-Vitro-Fertilization-Treatment - Oral Dydrogesterone has the potential to become new treatment of choice for an estimated 1.5 million women worldwide who undergo IVF treatment each year (1, 2) Wed, 08 Mar 2017 09:00:00 -0500 http://abbott.mediaroom.com/2017-03-08-New-Study-Results-May-Lead-to-a-New-Standard-of-Care-for-In-Vitro-Fertilization-Treatment Real-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose Monitoring and Improved Glucose Control for People with Diabetes http://abbott.mediaroom.com/2017-02-15-Real-World-Data-from-Abbotts-FreeStyle-R-Libre-Show-Association-Between-Higher-Frequency-of-Glucose-Monitoring-and-Improved-Glucose-Control-for-People-with-Diabetes - 409 million glucose measurements from more than 50,000 FreeStyle Libre users in Europe show people monitored their glucose levels on average 16 times per day Wed, 15 Feb 2017 08:30:00 -0500 http://abbott.mediaroom.com/2017-02-15-Real-World-Data-from-Abbotts-FreeStyle-R-Libre-Show-Association-Between-Higher-Frequency-of-Glucose-Monitoring-and-Improved-Glucose-Control-for-People-with-Diabetes